$MRTN·8-K

MARTEN TRANSPORT LTD · Jun 18, 4:01 PM ET

Compare

MARTEN TRANSPORT LTD 8-K

Research Summary

AI-generated summary

Updated

Marten Transport Ltd Amends Credit Agreement; Raises LC Sublimit to $35M

What Happened

  • Marten Transport Ltd (MRTN) filed a Form 8‑K (dated June 18, 2026) disclosing a First Amendment to its Credit Agreement with U.S. Bank National Association as agent and the participating banks. The original unsecured five‑year revolving credit facility (entered Aug 16, 2022) had an aggregate revolving amount up to $30.0 million and a $30.0 million sublimit for letters of credit. The June 12, 2026 amendment increases the letters‑of‑credit sublimit to $35.0 million, raises the maximum aggregate principal capacity from $100.0 million to $105.0 million, and provides an Amended and Restated Revolving Note with an aggregate principal amount of up to $35.0 million. Subsidiaries guarantee the obligations as described in the Credit Agreement.

Key Details

  • Amendment date: June 12, 2026; Form 8‑K filed June 18, 2026 (Item 1.01; Item 2.03).
  • Letters‑of‑credit sublimit increased from $30.0M to $35.0M.
  • Maximum aggregate principal capacity increased from $100.0M to $105.0M.
  • New Amended and Restated Revolving Note permits up to $35.0M in aggregate principal under the facility.

Why It Matters

  • The amendment increases Marten’s flexibility to support operations and collateral needs (more capacity for letters of credit and higher overall facility limit), which can help manage working capital or support business requirements without immediately issuing new long‑term debt. The facility remains unsecured and includes subsidiary guaranties as previously structured. Investors should view this as a change to the company’s short‑term liquidity arrangements; the filing does not state whether Marten has drawn additional funds under the amended terms. The actual impact depends on future borrowings or letter‑of‑credit usage. Exhibit 10.1 to the 8‑K contains the full amendment text.

Loading document...